Lyudmila Rakita
Psychiatry · Brockton, MANPI 1700873999
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 537 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 27.4% of the total. Reporting peaked in 2021 at $2,196 and has fallen 94.9% since, to $111 in 2023. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $11.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$773
- Lundbeck LLC$674
- Otsuka America Pharmaceutical, Inc.$665
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$554
- Vanda Pharmaceuticals Inc.$312
- plus $2K from 14 others
What the payments were for
- Food & beverage$5,97597%
- Education$1923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 139 | $1,689 |
| Sunovion Pharmaceuticals Inc. | 71 | $773 |
| Lundbeck LLC | 127 | $674 |
| Otsuka America Pharmaceutical, Inc. | 39 | $665 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $554 |
| Vanda Pharmaceuticals Inc. | 27 | $312 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $274 |
| Eisai Inc. | 21 | $258 |
| Teva Pharmaceuticals USA, Inc. | 9 | $211 |
| Alkermes, Inc. | 13 | $181 |
| Merck | 7 | $142 |
| Neurocrine Biosciences, Inc. | 6 | $110 |
| Johnson & Johnson | 7 | $102 |
| Neos Therapeutics, LP | 5 | $69 |
| Bausch Health US, LLC | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Corium, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$115
- ABILIFY MAINTENA$115
- LATUDA$109
How this compares
$6,168 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 11 | $685 |
| Olanzapine | 11 | $554 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $396 |
| Lamotrigine | 17 | $284 |
| Clonazepam | 24 | $278 |
| Trazodone Hcl | 13 | $124 |
| Lorazepam | 15 | $45 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Brockton
- Shahrzad SimsBrockton$34K
- Gary KaplanBrockton$11K
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Ernesto ZilberbergNorth Andover$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.